Below some of the highlights I found researching $AMBS
Below some of the highlights I found researching $AMBS again after 5Y+ or so. My opinion is that these highlights signal substantial positive change, but everyone should interpret it in their own way of course ..
Subsidiary / equity carve-outs complete;
Stakes in Todos & Emerald result in positive numbers on the balance sheet.
Improved IP, license, sublicense, JV, JC, royalty and, therefore, taxation structure.
All MANF research through university agreements where positive till date.
Positive results by Dr. Fumihiko Urano at Washington University regarding Wolfram.
Joana Neves is the 2019 grand prize winner of Sartorius & Science Prize for Regenerative Medicine & Cell Therapy.
Joana Neves + Buck Institute for Research on Aging + Years of government funding =
Neves discovered an evolutionarily conserved mechanism of tissue repair - immune modulation by the protein MANF - which she harnessed to restore visual function in old, blind mice with retinal disease.
Amarantus holds all licenses and patents.
Early this year Rob Rill takes substantial ownership into Todos Medical towards IPO.
IDEA Pharma to advise Amarantus on the road towards another successful IPO by them.
Enrollment for the LymPro PET 2.
Todos reports first commercial sales (government).
Todos Medical Enters Into Cross-Distribution Agreement With L1 Systems for Ventilators and COVID Testing
Todos Medical Signs Binding Term Sheet with HWH to market Blood Tests for Early Detection of BC.
Amarantus to operate in booming CBD market.
Researchers Claim CBD Can Modulate ACE-2 Expression In Gateway Tissues
Amarantus to operate in booming Telehealth market.
I probably forgot a few.
Almost forgot the Material Transfer Agreement with Dyadic International.
Highly speculative on my end:
Based on the above it could already mean that Amarantus is potentially receiving royalties (the later the annual filling, the more revenue to be stated?)
Feeling that ESS can only move forward after restructuring due to government regulations.
Feeling that MANF is part of one or multiple vaccine solutions. (E.g. Linebacker + Equivir).
Did Amarantus + ESS partake in project BioShield (BARDA)?
Did Amarantus + MANF partake in the panacea DARPA program?
Programs mentioned above and Geralds radio silence seem to correlate?
Last but not least, Amarantus to (reverse) merger with Dyadic?
These are my thoughts. Interpret the way you like. I’m positive.
Feel free to add and/or correct. Thanks.
2
Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Three proposed takeovers, three very different headaches, and one familiar question that never gets old: are regular shareholders actually receiving the best available deal? On Nov. 20, 2026, investor-rights law firm Halper Sadeh LLC said it was investigating the proposed transactions involving Penske Automotive Group, Werewolf Therapeutics and Personalis for potential...
Continue Reading
Rayong just became a much louder pin on Asia's industrial map. Birla Carbon has inaugurated a 120 kMT carbon black plant in Thailand, and the significance is bigger than a ribbon-cutting photo. This is a capacity-and-location move aimed squarely at the uncomfortable part of industrial supply chains: customers need material when they need it, not after it has spent weeks...
Continue Reading
Sydney just became the map pin for a fairly serious travel-content land grab. Trip.Best, Trip.com Group's ranking brand, has rolled out its 2027 Annual Rankings with coverage of all seven continents for the first time. This is not an earnings release, and nobody should pretend a hotel list magically turns into revenue by lunchtime. Still, the jump from 85 to 98 annual...
Continue Reading
Three ugly outages in four days can make even hardened technology buyers reconsider the sacred ritual of “patch immediately.” Mimic’s new Virtual Patching offering arrives squarely in that uncomfortable gap: a vulnerability is known, attackers may be moving fast, and the proper vendor update still needs testing before somebody detonates production. The company’s...
Continue Reading
Pet allergies and livestock disease are hardly glamorous, yet they are becoming a durable spending lane. The veterinary biologics market is projected to rise from $2.85 billion in 2026 to $3.69 billion by 2031, a 5.3% compound annual growth rate. That is not the kind of growth figure that makes anyone pound the table, and frankly it should not. It is the sort that can...
Continue Reading
Biologics labs are turning into a far better hunting ground for analytical equipment than the old, broad-brush research story suggests. Label-free detection is not a giant market, and nobody should dress it up as one. But the projected move from $0.58 billion in 2026 to $0.85 billion by 2031 points to a useful 8.1% annual growth lane, driven by work researchers genuinely...
Continue Reading
Robotics boards can get crowded with lofty nouns fast, and FFR just added another one with some real-world connective tissue behind it. Carolyn Kissane, associate dean at NYU's Center for Global Affairs, has joined as an independent director. The appointment is not a product launch, a contract, or revenue. It is a governance move. Still, in a business trying to weld...
Continue Reading
A $4.13 cash offer trading against a $7.17 close is the sort of thing that makes investors squint hard, and Verlinvest is practically waving a flag telling them why. This is not a conventional attempt to buy Oatly Group AB. It is a technical tender offer built to satisfy Swedish takeover rules while Verlinvest buys out its joint-venture partner’s interest in Oatly’s...
Continue Reading
Backup power gets interesting only after the grid has disappointed everybody. At Data Centre World Paris 2026, Ampace put its attention on that ugly, split-second handoff: utility power drops, a UPS has to catch the load immediately, and nobody operating an AI data centre gets to shrug if it does not. A Narrow Job With Brutal Consequences The company showcased its PU200...
Continue Reading
Two kids with real community ties just got a megaphone most grown-ups never receive. CVS Pharmacy has named Caroline, 9, of Holmes Beach, Florida, and Zoe, 12, of Los Angeles, as the first grand-prize winners of its Home Team Heroes youth soccer contest. Each player’s selected nonprofit soccer organization will receive a $25,000 grant, while their stories will appear on...
Continue Reading
Top 5 Most Recently Viewed Articles
Accessibility Insights for Website Rankings A recent study has highlighted a compelling correlation between website accessibility and search engine ranking. Through extensive research, it has become increasingly clear that adhering to accessibility guidelines significantly impacts organic search success. This analysis underscores the importance of making websites more...
Continue Reading
Back in 2025, CVS Health and Cigna took center stage with their new Medicare Advantage plans aimed squarely at seniors. The big pitch? Some members could enjoy $0 monthly premiums for essential prescription drugs—sounds great, right? But let's unpack that. Enrollment Window: Timing is Everything The enrollment period was set from October 15 to December 7, a critical...
Continue Reading
Kodiak AI and Ares Acquisition Corporation II Create a New Era in Autonomous Freight Kodiak AI, Inc., a revolutionary player in the autonomous vehicle space, is ready to ignite the future of freight logistics with its recent business combination with Ares Acquisition Corporation II. This pivotal step not only solidifies Kodiak's standing as a leader in AI-driven...
Continue Reading
TRON DAO Joins Forces with Chainlink for DeFi Advancement The TRON network is rapidly becoming a significant player in the decentralized finance (DeFi) space, boasting one of the largest DeFi economies globally. By collaborating with Chainlink through the Chainlink Scale program, TRON DAO is set to accelerate growth and improve adoption in its ecosystem. Chainlink Data...
Continue Reading
Canton Fair Showcases Sustainable Innovations for a Greener Future The ongoing Canton Fair has positioned itself as a leader in promoting environmental sustainability and innovation. A remarkable 10,040 companies are showcasing their offerings, highlighting over 300,000 green and low-carbon products. This huge gathering emphasizes the importance of eco-friendly solutions...
Continue Reading